Helsinn   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Tessin Switzerland (1976)

Organization Overview

First Clinical Trial
2004
NCT00090025
First Marketed Drug
2003
palonosetron (aloxi)
First NDA Approval
2003
palonosetron (aloxi)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

HELSINN | Helsinn Healthcare SA | HELSINN HLTHCARE | Helsinn Therapeutics (U.S.), Inc